Mounjaro wins bragging rights over Ozempic in a new weight-loss study—though it's one that was funded by the maker of ...

Weight loss jabs, also known as GLP-1 receptor agonists, work by reducing food cravings. Giving obese children weight-loss ...

Landmark' data has revealed a popular weight loss medicine slashes the risk of heart attack, stroke or heart disease death ...

Semaglutide can rapidly reduce heart attacks and other serious cardiovascular complications in adults with overweight or obesity who have pre-existing ...

New research being presented at this year's European Congress on Obesity (ECO 2025) has found that patients of an online obesity clinic achieved ...

In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of ...

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

As a Biden administration ban on so-called “junk fees” took effect Monday, Ticketmaster said it would start displaying the ...

When WW launched a new compounded semaglutide product late last year, the stock surged, renewing hopes of growth revival.

Weight loss drugs and jabs have become more popular and a recent study looked at the effectiveness of two drugs ...

A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s ...

Within six months, the drug reduced the risk of cardiovascular death by 50% and cut the risk of needing urgent treatment due ...